`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`PAR PHARMACEUTICAL, INC.,
`ARGENTUM PHARMACEUTICAL LLC, AND
`WEST-WARD PHARMACEUTICALS
`INTERNATIONAL LIMITED
`Petitioners,
`
`v.
`
`NOVARTIS AG
`Patent Owner
`_______________________
`Case IPR2016-014791
`Patent 9,006,224 B2
`_______________________
`
`
`PETITIONER’S UPDATED MANDATORY NOTICE
`PURSUANT TO 37 C.F.R. § 42.8(b)(1)
`
`
`
`
`1 Argentum Pharmaceutical LLC was joined as a party to this proceeding
`via a Motion for Joinder in IPR2017-0163; West-Ward Pharmaceuticals
`International Limited was joined as a party via a Motion for Joinder in
`IPR2017-01078.
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`
`West-Ward Pharmaceuticals International Limited (“West-Ward”) filed an
`
`IPR Petition on March 13, 2017, along with a Motion for Joinder with
`
`IPR2016-01479. West-Ward was joined as a party in IPR2017-01479 on
`
`September 25, 2017. At pages 3-4 of West-Ward’s Petition, in an abundance of
`
`caution, West-Ward identified the entities West-Ward Pharmaceuticals Corp. and
`
`Hikma Pharmaceuticals PLC as additional parties-in-interest.
`
`West-Ward Pharmaceuticals Corp. has changed its name to Hikma
`
`Pharmaceuticals USA Inc.. Accordingly, pursuant to 37 C.F.R. § 42.8(b)(1),
`
`West-Ward, in an abundance of caution, identifies Hikma Pharmaceuticals USA
`
`Inc. as an additional entity that is a real-party-in-interest who, going forward, may
`
`have control over this proceeding.
`
`
`
`Dated: July 31, 2018
`
`
`
`
`
`Respectfully submitted,
`
`By: /Marta E. Delsignore/
`Marta E. Delsignore (Reg. No. 32,689)
`
`Counsel for Petitioner West-Ward
`Pharmaceuticals International Limited
`
`1
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 31st day of July, 2018,
`
`a true and correct copy of the foregoing PETITIONER’S UPDATED
`
`MANDATORY NOTICE PURSUANT TO 37 C.F.R. § 42.8(b)(1) was served
`
`by electronic mail on Patent Owner’s lead and backup counsel at the following e-
`
`mail addresses:
`
`Nicholas N. Kallas
`Laura K. Fishwick
`Raymond R. Mandra
`Fitzpatrick, Cella, Harper & Scinto
`nkallas@fchs.com
`lfishwick@fchs.com
`rmandra@fchs.com
`ZortressAfinitorIPR@fchs.com
`
`
`
`
`
`
`
`
`
`
`and on Counsel for Petitioner Argentum Pharmaceuticals LLC at the following
`
`email addresses:
`
`Kevin Lawrence
`Matthew Phillips
`Laurence & Phillips IP Law LLP
`klaurence@lpiplaw.com
`mphillips@lpiplaw.com
`
`Tyler C. Liu
`Argentum Pharmaceuticals LLC
`tliu@agpharm.com
`
`
`
`
`
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`
`
`By: /Marta E. Delsignore/
`
`Marta E. Delsignore (Reg. No. 32,689)
`GOODWIN PROCTER LLP
`620 Eighth Avenue
`New York, NY 10018
`212-813-8822
`mdelsignore@goodwinprocter.com
`
`Counsel for Petitioner West-Ward
`Pharmaceuticals International Limited
`
`3
`
`